Our data indicate that treatment of AML cells with a combination of S63845 and ABT-737, a well-defined BCL-2/BCL-XL inhibitor, resulted in more effective cell killing compared to single-agent treatment. The gene discussed is BCL2; the disease is acute myeloid leukemia.